Aβ targeting therapies in ADNI

[Konstantinos Chiotis]

Hi,

I have been observing that the number of ADNI participants undergoing treatment with Aducanumab/Lecanemab/Donanemab has not been increasing in the last months to reflect the number of cases being treated in US academic centers since the approval of the agents. Are treated cases excluded from the latest ADNI protocol?

Kind regards,

Konstantinos

Konstantinos Chiotis, MD, PhD

[Albert G]

It's a very good question. If not where can we find such data?

Best regards,

Albert Guvenis,PhD

Precision Medical Systems

Institute of Biomedical Engineering

--
You received this message because you are subscribed to the Google Groups "Alzheimer's Disease Neuroimaging Initiative (ADNI) Data" group.
To unsubscribe from this group and stop receiving emails from it, send an email to adni-data+...@googlegroups.com.
To view this discussion visit https://groups.google.com/d/msgid/adni-data/1797a4f0-1ba6-4378-a3a0-84425128dd98n%40googlegroups.com.